In 1992, under the Prescription Drug User Fee Act (PDUFA), the U.S. Food and Drug Administration (FDA) began collecting fees from biopharmaceutical companies to provide much needed resources to keep new medicines moving through the approval process and into the hands of patients.
In 2003, through the Medicare Modernization Act, Congress established the Medicare prescription drug benefit - better known as Part D. Ten years later, at a cost significantly below initial estimates, the program is successfully providing affordable access to prescription drugs for more than 30 million seniors and people with disabilities.
From programs that provide access to medicines, to the development of innovative new treatments, the recent progress we’ve made is staggering.
Millions of patients around the world depend on innovative medicines to help them live long, healthy lives. Every time I travel to a different country, I am reminded of this fact. Just last week in Tokyo, PhRMA EVP for Advocacy Chip Davis specifically addressed how the innovative new medicines our member companies develop have enhanced the country’s health care system.
In 2003, the Medicare Prescription Drug, Improvement, and Modernization Act was passed by Congress and signed into law by President George W. Bush. This landmark legislation created the Medicare prescription drug benefit (Part D) – a federal program that provides affordable drug coverage to millions of seniors and people with disabilities.
Without patients who volunteer to participate in clinical trials, new medicines (including the 444 medicines in development to prevent and treat neurological disorders such as Parkinson’s) cannot be approved. The Michael J.
With more than 5,000 medicines in development globally, the prospects for incredible breakthroughs in medicine – many of which may one day help those suffering from diseases that are currently untreatable – are exceedingly bright.
As the nation recognizes World Alzheimer’s Day this Saturday, the federal government announced that it is awarding a $33.2 million grant to test an Alzheimer’s medicine in pre-symptomatic seniors (60 to 75 year olds) with two copies of the AD gene. According to a
In this austere fiscal environment, I must admit to being a little surprised by the news that the Food and Drug Administration (FDA) is spending $182,000 on a tool to monitorwhat people are saying about the Agency on social media.
A new paper released this week highlights issues surrounding the discussions on clinical trial data & The paper Clinical Trials and Data Transparency: The Public Interest Case, highlights specific problems to the current draft European Medicines Agency (EMA).
Delivering hope to millions of patients is the foundation of our industry. While the word 'hope' is highly personal to each patient, a common thread exists that unites all of us regardless of age, geographic location or socio-economic status. Without it, we would not be in a position to advance critical research that provides innovative new medicines to patients across the globe. By all accounts, 'hope' is the driver that keeps us looking forward.
There have been a number of media reports over the last week about the challenges surrounding Alzheimer’s research.
There are more than 5,000 new medications in the research and development pipeline. Some of these medications may one day result in effective treatments for diseases and conditions that exact a tremendous personal and financial toll on patients around the country and the world.
Biopharmaceutical scientists work daily to identify and develop potential preventative and therapeutic medicines for some of the most difficult conditions and diseases, with the unified goal of helping people live longer and healthier lives. Rarely have we been more successful at achieving this goal than with the development and global utilization of vaccines
It doesn't take long to understand why biopharmaceutical research companies have conducted more than 800 clinical trials in Montana.
So far this year, according to the Centers for Disease Control and Prevention (CDC), 159 cases of measles have been reported in 16 states – 36 percent of those occurring in children less than five years of age.
Despite some tremendous strides in vaccine development over the years, vaccines remain a major public health challenge for patients and their families throughout the world. This week we released our Medicines in Development: Vaccines report, which shows there are more than 270 vaccines in the pipeline to prevent and/or treat a wide array of diseases, including various forms of cancer and neurological disorders.
Turkey is at the vanguard of a global trend of implementing universal health coverage. Building on that leadership position, Prime Minister Erdoğan has set a goal for Turkey to become a global leader in the delivery of health services over the next decade. A key element of developing the health care market in Turkey is expanding the country’s biopharmaceutical sector.